| Literature DB >> 2941960 |
L Falsetti, D Dordoni, C Gastaldi, A Gastaldi.
Abstract
The authors treated 28 patients with polycystic ovary syndrome (PCOS) with the new preparation SH B 209 AE consisting of 0.035 mg of ethinylestradiol and 2 mg of cyproterone acetate (EE + CPA) throughout 12 months. From the analysis of the endocrine and clinical modifications induced by the drug along with the negligible incidence of side effects the conclusion can be drawn that this new estro-progestational association is indicated in the therapy of PCOS.Entities:
Keywords: Acne--prevention and control; Androgens; Biology; Clinical Research; Contraception; Contraceptive Agents, Estrogen--therapeutic use; Contraceptive Agents, Female--therapeutic use; Contraceptive Agents--therapeutic use; Dermatitis; Dermatological Effects; Diseases; Economic Factors; Endocrine Effects; Endocrine System; Ethinyl Estradiol--therapeutic use; Family Planning; Genital Effects, Female; Genitalia; Genitalia, Female; Hair Diseases; Hirsutism--prevention and control; Hormones; Ovarian Cysts--prevention and control; Ovarian Effects; Ovary; Physiology; Reproductive Control Agents; Research And Development; Research Methodology; Signs And Symptoms; Technology; Treatment; Urogenital Effects; Urogenital System
Mesh：
Substances：
Year: 1986 PMID： 2941960
Source DB: PubMed Journal: Acta Eur Fertil ISSN： 0587-2421